Table 4

Outcomes for patients with Guillain-Barré syndrome (GBS) following SARS-CoV-2 vaccination

OutcomeGBS after SARS-CoV-2 vaccination (n=70)
Maximum level of care
 Outpatient4/70 (6%)
 Medical ward50/70 (71%)
 High dependency unit6/70 (9%)
 Intensive care unit10/70 (14%)
Discharge destination
 Usual place of residence46/70 (66%)
 Medical ward9/70 (13%)
 Rehabilitation13/70 (18%)
 Died during admission2/70 (3%)
Duration of admission
 Median (IQR)13.5 days (8–28.5; for n=52)
GBS disability score at 3 months
 No symptoms (score 0)5/59 (9%)
 Symptomatic but able to run (score 1)20/59 (34%)
 Able to walk independently, but unable to run (score 2)9/59 (15%)
 Mobilising with aids (score 3)13/59 (15%)
 Wheelchair bound or bedbound (score 4)9/59 (15%)
 Ventilated for at least a part of the day (score 5)1/59 (2%)
 Died (score 6)2/59 (3%)
Further SARS-CoV-2 vaccination
 Yes7/70 (10%)*
  • Further three patients (two with sensorimotor AIDP and one with facial diplegia with paraesthesias variant) who initially received ChAdOx1 opted to receive BNT162b2 for their second dose. For all, the GBS was classified as probably linked with the vaccine. None had any new symptoms or deterioration.

  • *Four patients (three with classic sensorimotor AIDP and one with facial diplegia with paraesthesias variant) received a second dose of the same SARS-CoV-2 vaccine after their acute illness. One, whose GBS had been classified as unlikely linked to the vaccine, had a further dose of BNT162b2; one, whose GBS was possibly linked to the vaccine, had ChAdOx1; and two, whose GBS was classified as probably linked, had a further dose of ChAdOx1. None had any new symptoms or deterioration.

  • AIDP, acute inflammatory demyelinating polyneuropathy.;